FDA says the move boosts regulatory transparency, offering insights into common approval barriers in drug applications and reducing guesswork.

AL amyloidosis is caused by abnormal plasma cells in the bone marrow, which produce misfolded amyloid proteins that circulate in the blood, then build-up in the heart, kidney, liver, and other organs.